Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV

  • Co-infections and Comorbidity (S Naggie, Section Editor)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Persons with HIV are at a higher risk for acquiring HBV (hepatitis B virus) than the general population due to shared modes of transmission and are significantly more likely to develop and die from sequelae of chronic HBV infection. Early vaccination is key to achieving HBV protective immunity, but response rates are still much lower than in the general population, ranging from 35 to 70%. Individuals with HIV also experience more rapidly waning immunity than those without HIV. Strategies to augment initial response and improve long-term immunity in individuals with HIV include alterations in dose, frequency, and the use of immune adjuvants.

Recent Findings

Recent studies have focused on the use of different vaccine formulations, the use of vaccine adjuvants, increased number and strength of vaccine dosages, increased dose frequency, alternative routes of administration, dual vaccinations, and the use of booster vaccines. Although no consensus has been reached on the use of certain vaccination regimens, three and four double-dose vaccine schedules via the intramuscular route have demonstrated higher initial response rates. Early vaccination when CD4 cell counts are greater than 350/mm3 with low viral loads has been shown to improve initial response, along with completion of immunization series. Adjuvants such as TLR4 and TLR9 agonists appear to improve response to HBV vaccination, but further research is needed in individuals with HIV.

Summary

Persons with HIV have significant lower initial and long-term seroresponse rates after HBV vaccination than immunocompetent individuals. Recent and ongoing studies continue to evaluate multiple strategies to improve these rates within a uniquely susceptible population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol. 2014;20(40):14598–614. https://doi.org/10.3748/wjg.v20.i40.14598.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Crum-Cianflone NF, Sullivan E. Vaccinations for the HIV-infected adult: a review of the current recommendations. Part I Infect Dis Ther. 2017;6(3):303–31. https://doi.org/10.1007/s40121-017-0166-x.

    Article  PubMed  Google Scholar 

  3. Phung BC, Sogni P, Launay O. Hepatitis B and human immunodeficiency virus co-infection. World J Gastroenterol. 2014;20(46):17360–7. https://doi.org/10.3748/wjg.v20.i46.17360.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–13. https://doi.org/10.1001/jama.2018.3795.

    Article  CAS  PubMed  Google Scholar 

  5. Soriano V, Poveda E, Vispo E, Barreiro P. Hepatitis B in HIV-infected patients. Clin Liver Dis. 2013;17(3):489–501. https://doi.org/10.1016/j.cld.2013.05.008.

    Article  PubMed  Google Scholar 

  6. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921–6. https://doi.org/10.1016/S0140-6736(02)11913-1.

    Article  PubMed  Google Scholar 

  7. HIV Infection and Adult Vaccination. Centers for Disease Control. https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/hiv.html. Accessed March 1, 2019.

  8. Table 1. Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2019. Centers for Disease Control. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html. Accessed March 1, 2019.

  9. Table 2. Recommended Adult Immunization Schedule by Medical Condition and Other Indications, United States, 2019. Centers for Disease Control. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. Accessed March 1, 2019.

  10. Hadler SC, Francis DP, Maynard JE, Thompson SE, Judson FN, Echenberg DF, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med. 1986;315(4):209–14. https://doi.org/10.1056/NEJM198607243150401.

    Article  CAS  PubMed  Google Scholar 

  11. Landrum ML, Hullsiek KH, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS. 2010;24(4):545–55. https://doi.org/10.1097/QAD.0b013e32832cd99e.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Trantham L, Kurosky SK, Zhang D, Johnson KD. Adherence with and completion of recommended hepatitis vaccination schedules among adults in the United States. Vaccine. 2018;36(5):5333–9. https://doi.org/10.1016/j.vaccine.2018.05.111.

    Article  PubMed  Google Scholar 

  13. Dentinger CM, McMahon BJ, Butler JC, Dunaway CE, Zanis CL, Bulkow LR, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24(9):786–92. https://doi.org/10.1097/01.inf.0000176617.63457.9f.

    Article  PubMed  Google Scholar 

  14. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333–41. https://doi.org/10.7326/0003-4819-142-5-200503010-00008.

    Article  PubMed  Google Scholar 

  15. McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–6. https://doi.org/10.1086/606119.

    Article  CAS  PubMed  Google Scholar 

  16. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis. 2016;214(1):16–22. https://doi.org/10.1093/infdis/jiv748 This study provided 30-year data on a large cohort of HBV-vaccinated Alaska natives and demonstrated ≥ 90% HBV seroprotection in an immunocompetent population.

    Article  CAS  PubMed  Google Scholar 

  17. Panel on opportunistic infections in HIV-infected adults and adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed March 1, 2019.

  18. Piroth L, Launay O, Michel M, Bourredjem A, Miailhes P, Ajana F, et al. Vaccination against hepatitis B virus (HBV) in HIV-1-infected patients with isolated anti-HBV core antibody: the ANRS HB EP03 CISOVAC prospective study. J Infect Dis. 2016;213(11):1735–42. https://doi.org/10.1093/infdis/jiw011 This prospective cohort study of patients with HIV and isolated anti-HBc found benefit in double-dose revaccination if initial vaccine elicited anti-HBs ≤ 100 mIU/ml.

    Article  CAS  PubMed  Google Scholar 

  19. Chakvetadze C, Bani-Sadr F, Pendeven CL, Lescure FX, Fontaine C, Galperine T, et al. Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen. Clin Infect Dis. 2010;50(8):1184–886. https://doi.org/10.1086/651422.

    Article  PubMed  Google Scholar 

  20. Kaech C, Pache I, Bürgisser P, Elzi L, Darling KEA, Cavassini M. Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen. J Inf Secur. 2012;65(2):157–64. https://doi.org/10.1016/j.jinf.2012.03.009.

    Article  Google Scholar 

  21. Fuster F, Vargas JI, Jensen D, Sarmiento V, Acuña P, Peirano F, et al. CD4/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: a prospective cohort study. Vaccine. 2016;34(16):1889–95. https://doi.org/10.1016/j.vaccine.2016.02.055.

    Article  CAS  PubMed  Google Scholar 

  22. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12(12):966–76. https://doi.org/10.1016/S1473-3099(12)70243-8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Flynn PM, Cunningham CK, Rudy B, Wilson CM, Kapogiannis B, Worrell C, et al. Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens. J Acquir Immune Defic Syndr. 2011;56(4):325–32. https://doi.org/10.1097/QAI.0b013e318203e9f2.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Landrum ML, Hullsiek KH, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, et al. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine. 2009;27(34):4731–8. https://doi.org/10.1016/j.vaccine.2009.04.016.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cruciani M, Mengoli C, Serpelloni G, Lanza A, Gomma M, Nardi S, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine. 2009;27(1):17–22. https://doi.org/10.1016/j.vaccine.2008.10.040.

    Article  CAS  PubMed  Google Scholar 

  26. Fonseca MO, Pang LW, de Paula CN, Barone AA, Heloisa LM. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23(22):2902–8. https://doi.org/10.1016/j.vaccine.2004.11.057.

    Article  CAS  PubMed  Google Scholar 

  27. Pessoa SD, Miyamoto M, Ono E, Gouvêa AF, de Moraes-Pinto MI, Succi RC. Persistence of vaccine immunity against hepatitis B virus and response to revaccination in vertically HIV-infected adolescents on HAART. Vaccine. 2010;28(6):1606–12. https://doi.org/10.1016/j.vaccine.2009.11.045.

    Article  CAS  PubMed  Google Scholar 

  28. del Pozo Balado MdM, Leal M, Méndez Lagares G, Mata RC, López-Cortés LF, Viciana P et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J Infect Dis 2010;202(3):362–369. doi:https://doi.org/10.1086/653707.

  29. Mehta N, Cunningham CK, Flynn P, Pepe J, Obaro S, Kapogiannis BG, et al. Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. Vaccine. 2010;28(21):3672–8. https://doi.org/10.1016/j.vaccine.2010.03.022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Landrum ML, Hullsiek KH, Chun HM, Crum-Cianflone NF, Ganesan A, Weintrob AC, et al. The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis. Am J Epidemiol. 2011;173(1):84–93. https://doi.org/10.1093/aje/kwq326.

    Article  PubMed  Google Scholar 

  31. Mena G, Llupià A, García-Basteiro AL, Díez C, León A, García F, et al. Assessing the immunological response to hepatitis B vaccination in HIV-infected patients in clinical practice. Vaccine. 2012;30(24):3703–9. https://doi.org/10.1016/j.vaccine.2012.03.018.

    Article  CAS  PubMed  Google Scholar 

  32. Launay O, van der Vliet D, Rosenberg AR, Michel ML, Piroth L, Rey D, et al. ANRS HB03 VIHVAC-B Trial. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305(14):1432–40. https://doi.org/10.1001/jama.2011.351.

    Article  CAS  PubMed  Google Scholar 

  33. Launay O, Rosenberg AR, Rey D, Pouget N, Michel ML, Reynes J et al. Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1: secondary analysis of a randomized clinical trial. JAMA Intern Med. 2016;176(5):603-10. doi:https://doi.org/10.1001/jamainternmed.2016.0741. This follow-up study of a randomized controlled trial demonstrated improved long-term immunity in patients with HIV following an intramuscular double-dose vaccine regimen.

  34. Bunupuradah T, Ananworanich J, Pancharoen C, Petoumenos K, Prasitsuebsai W, Wongngam W, et al. Randomized study of intradermal compared to intramuscular hepatitis B vaccination in HIV-infected children without severe immunosuppression. Vaccine. 2011;29(16):2962–7. https://doi.org/10.1016/j.vaccine.2011.01.114.

    Article  CAS  PubMed  Google Scholar 

  35. Potsch DV, Oliveira MLA, Ginuíno C, Miguel JC, Oliveira SAN, Silva EF, et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine. 2010;28(6):1447–50. https://doi.org/10.1016/j.vaccine.2009.11.066.

    Article  CAS  PubMed  Google Scholar 

  36. Potsch DV, Camacho LAB, Tuboi S, Villar LM, Miguel C, Ginuíno C, et al. Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults. Vaccine. 2012;30(41):5973–7. https://doi.org/10.1016/j.vaccine.2012.07.028.

    Article  CAS  PubMed  Google Scholar 

  37. Kourkounti S, Retsas T, Paparizos V, Tsimpidakis A, Kapsimali V, Rigopoulos D. Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load. Vaccine. 2018;36(12):1533–6. https://doi.org/10.1016/j.vaccine.2018.02.018.

    Article  PubMed  Google Scholar 

  38. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, et al. A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients. J Infect Dis. 2011;203(7):984–91, de Vrie. https://doi.org/10.1093/infdis/jiq137.

    Article  PubMed  Google Scholar 

  39. Irungu E, Mugo N, Ngure K, Njuguna R, Celum C, Farquhar C, et al. Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya. J Infect Dis. 2013;207(3):402–10. https://doi.org/10.1093/infdis/jis695.

    Article  CAS  PubMed  Google Scholar 

  40. Rey D, Piroth L, Wendling MJ, Miailhes P, Michel ML, Dufour C, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infect Dis. 2015;15(11):1283–91. https://doi.org/10.1016/S1473-3099(15)00220-0.

    Article  CAS  PubMed  Google Scholar 

  41. Chaiklang K, Wipasa J, Chaiwarith R, Praparattanapan J, Supparatpinyo K. Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial. PLoS One. 2013;8(11):e80409. https://doi.org/10.1371/journal.pone.0080409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ni JD, Xiong YZ, Wang XJ, Xiu LC. Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis? Int J STD AIDS. 2013;24(2):117–22. https://doi.org/10.1177/0956462412472309.

    Article  CAS  PubMed  Google Scholar 

  43. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005;19(14):1473–9. https://doi.org/10.1097/01.aids.0000183514.37513.d2.

    Article  CAS  PubMed  Google Scholar 

  44. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis. 2008;46(8):1310–4. https://doi.org/10.1086/533467.

    Article  CAS  PubMed  Google Scholar 

  45. Angel JB, Cooper CL, Clinch J, Young CD, Chenier A, Parato KG, et al. CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. J Immune Based Ther Vaccines. 2008;6:4. https://doi.org/10.1186/1476-8518-6-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. de Silva TI, Green ST, Cole J, Stone BJ, Dockrell DH, Vedio AB. Successful use of Fendrix in HIV-infected non-responders to standard hepatitis B vaccines. J Inf Secur. 2014;68(4):397–9. https://doi.org/10.1016/j.jinf.2013.12.009.

    Article  Google Scholar 

  47. Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine. 2012;30(15):2556–63.

    Article  CAS  Google Scholar 

  48. Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine. 2013;31(46):5300–5. https://doi.org/10.1016/j.vaccine.2013.05.068.

    Article  CAS  PubMed  Google Scholar 

  49. Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36(5):668–74. https://doi.org/10.1016/j.vaccine.2017.12.038.

    Article  CAS  PubMed  Google Scholar 

  50. Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine. 2013;31(46):5306–13. https://doi.org/10.1016/j.vaccine.2013.05.067.

    Article  CAS  PubMed  Google Scholar 

  51. Kernéis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boëlle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130–9. https://doi.org/10.1093/cid/cit937.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lopes VB, Hassing RJ, de Vries-Sluijs TE, El Barzouhi A, Hansen BE, Schutten M, et al. Long-term response rates of successful hepatitis B vaccination in HIV-infected patients. Vaccine. 2013;31(7):1040–4. https://doi.org/10.1016/j.vaccine.2012.12.047.

    Article  PubMed  Google Scholar 

  53. Abzug MJ, Warshaw M, Rosenblatt HM, Levin MJ, Nachman SA, Pelton SI, et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis. 2009;200(6):935–46. https://doi.org/10.1086/605448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Lara AN, Sartori AM, Fonseca MO, Lopes MH. Long-term protection after hepatitis B vaccination in people living with HIV. Vaccine. 2017;35(33):4155–61. https://doi.org/10.1016/j.vaccine.2017.06.040.

    Article  PubMed  Google Scholar 

  55. Geretti AM, Doyle T. Immunization for HIV-positive individuals. Curr Opin Infect Dis. 2010;23(1):32–8. https://doi.org/10.1097/QCO.0b013e328334fec4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Digestive Diseases, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267-0595, USA

    Priya D. Farooq & Kenneth E. Sherman

Authors
  1. Priya D. Farooq
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth E. Sherman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth E. Sherman.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Co-infections and Comorbidity

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Farooq, P.D., Sherman, K.E. Hepatitis B Vaccination and Waning Hepatitis B Immunity in Persons Living with HIV. Curr HIV/AIDS Rep 16, 395–403 (2019). https://doi.org/10.1007/s11904-019-00461-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-019-00461-6

Keywords

Search

Navigation